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Access to human reproductive tissue is essential for many forms of stem cell research. We identify questions
for future studies of tissue providers, procurers, and end-user scientists, and suggest that international
comparative studies of all three parties, and of the relationships between them, will improve the ethical
supply of tissue.Many stem cell scientists are dependent
on a supply of human reproductive tissues
(hRT), such as eggs, embryos, fetal tissue,
and placentas, to conduct their research.
The processes through which that tissue
arrives in the laboratory might be consid-
ered of little importance to many bench
scientists, but we suggest that the field
of stem cell research would benefit from
an active interest in the relationships
between those asked to provide tissue
(oftenpatients), thoseacquiring that tissue
(often, but not only, IVF clinicians), and
those using that tissue (stem cell scien-
tists). Understanding the interactions
between these three key parties will help
to ensure an ethical and efficient supply
of hRT.
A growing body of research on actual
and potential tissue providers supplies
important insights into their reasons for
giving or not giving tissue. We suggest
that this research is a useful foundation
for developing studies of the roles, values,
and experiences of the other two parties
and for studying the relationshipsbetween
all three.
In this article we use current knowledge
to identify questions for future studies
into this important aspect of stem cell
research.
Why Is Knowledge about These
Relationships Important for Stem
Cell Scientists?
Scientists wish to contribute to the greater
good through the development of treat-
ments for serious illnesses. They can
only achieve this goal by ensuring
a regular supply of a range of hRT. Such
tissue does not just arrive, silently and
seamlessly, into the laboratory, but hasto be actively sought. Sometimes it even
has to be fought for politically, as the
USA Lamberth ruling indicates; there is
a need to build trust in this ‘‘sensitive’’
area (Gottweis, 2010). One element of
that trust is ensuring that tissue is
acquired ethically, through understanding
what is important to tissue providers,
tissue procurers, research funders, and
wider society.
While trust is not the only aspect that
requires examination in this complex field,
it is considered central to the successful
acceptance of developments in medicine,
science, and biotechnology, as is the
need to overcome undeserved mistrust
(O’Neill, 2002). Evidence of a lack of trust
ranges from the concerns raised by the
Henrietta Lacks case (Skloot, 2010) to
media (mis)representations of stem cell
research to ‘‘society’s doubt about the
implications of science and its concerns
about the hubris of scientists’’ (Moreno,
2010; p. 1031).
The building of trust relationships needs
tobeaddressed internationally, as acorol-
lary to the global demand for hRT for
research. ‘‘Scientific tourism’’ (scientists
traveling around the world to work under
regulatory conditions more favorable to
their research) is understandable within
the ambitions of the therapeutic promise,
but needs to be tempered by awareness
of the processes of tissue transactions
within any particular country. The provi-
sion and procurement of hRT varies
between different cultural, regulatory,
and ethical frameworks; scientists need
to be aware of these variations and of their
implications for the ethical conduct of
their laboratory work. While the ‘‘Hwang
scandal’’ is past history, the focus ofCell Stem Cattention, demonstrated by the recogniz-
able shorthand reference, was as much
the scientist who acquired and (mis)used
the tissue as the fabricated results. The
scandal is a reminder of the need to
ensure that everyday practices of tissue
procurement and use are not achieved
at ethical cost to tissue providers, or at
a cost to the trust relationship between
all three parties.
Paradoxically, ethical safeguards can
inhibit the involvement of scientists in
procuring tissue. For example, the UK
Polkinghorne Guidelines for acquiring
fetal tissue for research enshrine the
‘‘principle of separation,’’ which ensures
that researchers have no direct contact
with potential tissue providers (Woods
and Taylor, 2008). While valuable in pro-
tecting the autonomy of tissue providers,
this principle can have the unintended
effect of limiting the knowledge and
understanding between providers and
scientists. Trust exists in the context of a
relationship between two or more parties;
one of its components, openness, is
enhanced by communication. If the sepa-
ration principle means that that communi-
cation has to be taken on by mediating
tissue procurers, then the need for all
three parties to understand each other’s
actions and motivations is reinforced.
Insights from Studies of Potential
Tissue Providers
There is a growing body of evidence-
based research on the providers of
varying types of hRT. These studies are
valuable for understanding what matters
to potential and actual providers and for
identifying useful questions to ask of the
other two parties.ell 8, June 3, 2011 ª2011 Elsevier Inc. 613
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studies of the disposition decisions of
coupleswith frozenembryos (foradetailed
review of this international research, see
Haimes and Taylor, 2010). Collectively,
these studies indicate that most couples
have great difficulty in committing to
a decision and that none of the available
options, including giving to research, is
ideal. What might appear an obvious
source of research materials is, to the
potential providers, a series of complex
challenges (Lyerly et al., 2011). These find-
ings suggest that understanding tissue
provision from the potential providers’
viewpoint reveals factors that need to be
addressed (e.g., through robust consent,
and other, practices) if greater levels of
provision are to be achieved (Kalista
et al., 2011).
In a rare empirical study of providers of
fresh embryos for hESC research (Haimes
and Taylor, 2009), interviewees were
preoccupied with IVF treatment and their
overriding concern to have a baby. The
request to provide fresh embryos to
research was a secondary consideration
and judged in relation to its effect on their
chances of pregnancy. Producing eggs
and then embryos was interviewees’
initial goal because these steps repre-
sented the vital early markers of success
without which no baby could result. In
other words, eggs and embryos were
both extremely valuable to the patients;
few interviewees were prepared to give
away eggs for research until fertilization
had been attempted. Eggs are therefore
not morally simple material, as is often
assumed; they caused interviewees as
many dilemmas as embryos, at that stage
of their treatment. This finding suggests
that attention should be paid to the careful
timing of requests for fresh embryos and
eggs. Although interviewees referred to
the importance of ‘‘the embryo,’’ the
morally laden, abstract entity that they
knew was the subject of debate and
which they felt deserved respect, it did
not play a dominant role in their decision
making. Such findings suggest that the
moral status of the human embryo can
be accorded a less determining role in
ethical analyses of hESC research.
Considered together, research on
providers of frozen and fresh embryos
suggests two other important issues: (1)
that providers do not necessarily share
clinicians’, scientists’, nor regulators’614 Cell Stem Cell 8, June 3, 2011 ª2011 Elsdefinitions of what constitutes ‘‘spare’’
embryos or eggs; and (2) that attention
needs to be paid to the specific features
of the clinical context in which people
are asked to provide hRT.
The study on fresh embryo provision
suggested that a study on the provision
of fresh eggs for research was necessary,
since it was clear that egg provision is less
ethically straightforward than might have
been supposed. An ongoing study of
volunteers to a controversial ‘‘egg sharing
for research’’ scheme (which involves the
provision of eggs for SCNT research
in exchange for reduced IVF fees) may
offer additional insight. The theoretical
literature on this, and other schemes
encouraging egg provision for research,
debates the ethics of inducement, exploi-
tation, and commodification. However,
the fresh embryo project (Haimes and
Taylor, 2009) suggests that egg providers
will have other insights to add, including
what personal, social, and economic
factors persuade potential tissue pro-
viders to become active volunteers to
such a scheme, given what is now known
about how precious these eggs are to IVF
patients.
Pfeffer (2008) adds to this work on
providers through a study of women who
gave fetal tissue from abortions to stem
cell researchers. During focus group
discussions women realized they had
not understood the implications of the
successful derivation of stem cell lines
from their tissue. The association of these
lines with ‘‘renewal, regeneration, and
immortality’’ reinforced the physical
reality of the fetus which was ‘‘the very
thing abortion is meant to eliminate’’
(p. 2544). This greater knowledge meant
women started to doubt their decision.
This finding suggests that scientists
and tissue procurers need to acknowl-
edge and address such contradictions,
perhaps by emphasizing the hoped-for,
longer-term benefits of research.
This research on providers of embryos
(frozen and fresh), eggs, and fetal tissue
is a valuable beginning, but further
questions can be asked, comparing and
contrasting potential and actual providers
of a wider range of tissues in awider range
of countries. Some examples are as
follows.
(1) Do different types of hRT (e.g.,
eggs, sperm, embryos, fetuses,evier Inc.placentas, umbilical cords, amni-
otic membranes, and fluids) raise
different issues for potential
providers? Howmight these be ad-
dressed, to the providers’ satisfac-
tion, so that they turn from being
potential to actual providers?
(2) Research tissue is often described
as ‘‘spare,’’ ‘‘surplus,’’ or ‘‘waste:’’
is this how potential hRT providers
view their materials (the studies on
embryo disposition suggest other-
wise)?
(3) Does the typeof intended research,
or aparticular research team, affect
the decision to provide hRT? What
do potential providers want to
know about the research?
(4) How do potential hRT providers
define and measure costs and
benefits of provision?
(5) What measures would potential
hRT providers suggest to ensure
ethical protection?
(6) What do hRT providers regard as
effective practices and policies
in encouraging provision? Who
would they prefer to discuss their
decisions with?
(7) How do hRT providers concep-
tualize their contribution: as dona-
tions, gifts, altruism, sharing, ex-
changing, or selling? Does this
affect their decision?
(8) What other factors affect their
decision making? How do these
compare with what clinicians, sci-
entists, and policymakers assume
to be important to providers?
Without such comparative studies
and evidence-based conclusions, we
are reduced to speculating about what
encourages people to supply tissue
for research, what discourages them,
and why.The Role of Tissue Procurers
Even this brief indication of what can be
learnt from studying providers suggests
the usefulness of studying those tasked
with the pivotal role of procuring tissue
to see how they manage this process.
Attention has been given to the ethics
of arrangements for acquiring tissue
(such as the impact of different consent-
ing procedures; Cohen et al., 2008),
but less is known about how tissue pro-
curers implement these arrangements
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their activities are affected by their rela-
tionships with tissue providers and with
the end user scientists. Important ques-
tions to ask (again across the full range
of tissues and countries) include the
following.
(1) Who are the tissue procurers?
(2) What motivates them to act as go-
betweens and how does this affect
how they do their main jobs?
(3) How do they think they should
conduct their professional relation-
ships with providers and with
scientists? Do they see themselves
as advocates for the science, the
providers, or both?
(4) What value do they place on
measures such as inducements to
provide tissue?
(5) Are there any patients, clinical
settings, or types of tissue that
they feel should not be included in
requests to help research? If so,
why?
(6) How might they be assisted to do
a more effective job, within robust
ethical guidelines?
Acknowledging the global variations
in tissue acquisition, it is also important
to ask whether tissue transactions
between providers and procurers take
place under fair social and economic
conditions or whether local inequalities
and injustices skew such negotiations.
These questions are open to empirical
investigation.
The Views and Experiences of Stem
Cell Scientists
Scientists’ collaborations with procurers
can benefit from a greater understanding
of what is actually involved in acquiring
tissues, to make these transactions more
effective and efficient while still ethically
acceptable. This suggests, however, that
there are also useful studies to be con-
ducted with scientists, to understand
how they see their role in these tissue
transactions. Questions might include the
following.(1) How much do scientists know
about how hRT arrives in their labo-
ratories?
(2) Do scientists regard themselves
as having any responsibility for
the ethical procurement of hRT?
Would they like a direct involve-
ment in acquiring tissue?
(3) Do scientists see a need to build
trust relationships with tissue
providers, procurers, and wider
society? If so, how might they do
this?
(4) What do scientists regard as effec-
tive practices in encouraging provi-
sion? How do these compare with
the experiences of providers and
procurers?
(5) Do scientists view different types
of hRT differently in terms of how
they should be provided, acquired,
and used?
(6) How influential are the legal,
ethical, and cultural contexts in
which they work in shaping their
research?
(7) Is stem cell science the same or
different from other areas of re-
search in terms of how human
tissue should be provided, pro-
cured, and used?
These questions are just the tip of an
investigatory iceberg; others will emerge
through research and debate. Given that
many stem cell scientists have to play an
increasingly public role in defending and
promoting their work, it is important for
them to know more about other parties’
practices and experiences in this contro-
versial aspect of their work, to assist them
to provide an evidence-based advocacy.Next Steps
Studying tissue providers and procurers,
their relationships with each other, and
their relationship with stem cell scientists
enables scrutiny of the highly complex
moral, cultural, economic, and political
transactions that underpin the uses of
hRT in research. It also assists the identi-
fication of any misunderstandings andCell Stem Cgaps in communication between all three
parties, thereby building more trust
between them and improving the ethical
and efficient acquisition of hRT for
research. A more detailed understanding
of tissue transactions will also assist
scientists to tailor messages about the
need for tissue and about the long-term
benefits of contributing to scientific
research. Therefore a constant question-
ing of the processes of acquiring hRT by
all those involved is essential to improving
best practice.
These outcomes will be more robust if
future investigations (1) encompass the
full range of hRT; (2) include a wider range
of countries; (3) combine the perspectives
of all three parties; (4) integrate socioeth-
ical collaborations within large-scale
stem cell projects; (5) learn from tissue
transactions in other areas of scientific
research; and (6) combine to produce up-
dated, evidence-based policy and prac-
tice guidelines for all those involved.
The work of scientists depends on the
trust of wider society, so it is in the inter-
ests of all those engaged in stem cell
science to attend to these issues.
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